MAP2K7 and neuroblastoma: Overall, the systematic high throughput screening of cell lines reflecting the range between adrenergic to mesenchymal neuroblastoma cell lines, revealed a specific sensitivity of mesenchymal neuroblastoma cell lines to MEK inhibitors, confirmed by higher expression of the MAPK inhibitor sensitivity and the MAPK pathway activity gene signature.